Rett Syndrome — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Rett syndrome and real-world treatment patterns of trofinetide in the United States.
Rashid Nazia et al. — Journal of medical economics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42287113/
- 2.
Unexpectedly competent immune response to SARS-CoV-2 vaccination in Rett syndrome.
Soldateschi Ludovica et al. — Human vaccines & immunotherapeutics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41605700/
- 3.
Variability-dominated auditory cortical dysfunction and targeted VNS modulation in a Mecp2
Tahmasebi Ghazaal et al. — Experimental neurology (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42103206/
- 4.
Aromatic Cage-Directed Azide-Methyllysine Photochemistry for Profiling Nonhistone Interacting Partners of the MeCP2 Methyl-CpG-Binding Domain.
Padhan Jyotirmayee et al. — Biochemistry (3 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42397176/
- 5.
A functional MeCP2-LBX1 axis regulates neuronal gene expression in neuronal cells.
Horike Shin-Ichi et al. — Biochemical and biophysical research communications (2 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42054896/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
Recruiting — Phase 3 — Biomed Industries, Inc.
https://clinicaltrials.gov/study/NCT06840496
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Rett Syndrome
Rett syndrome is a rare genetic condition that affects brain development, mainly in girls. After a period of typical early development, children lose purposeful hand skills and speech. Research into gene therapies and other treatments is progressing.
Most Recent Research
BACKGROUND: Trofinetide (TROF) remains the first and only FDA-approved pharmacologic treatment for Rett syndrome (RTT). There is limited real-world evidence on TROF use, restarts, dosing patterns and predictors of non-persistence. This study evaluated long-term treatment patterns and baseline predictors of non-persistence among RTT individuals initiating TROF. METHODS: A retrospective claims analysis of linked IQVIA Anonymized Patient Level Data and TROF pharmacy data (1 January 2021 to 30 September 2024) was performed. RTT individuals initiating 1st TROF prescription (RX) between 1 April 2023 and 31 March 2024 with ≥6 months of pre- and post-index continuous enrollment were classified as persistent (gap ≤90 days) and non-persistent. Median (IQR) time on treatment was analyzed, and Kaplan-Meier assessed time to non-persistence. Restarts among non-persistent were examined. Dosing patterns such as mean dose in milligrams (mg) and percentage target daily dose (%TDD) at each RX were evaluated. Predictors of non-persistence were assessed using logistic regression. RESULTS: Among 1,175 TROF initiators, 54.9% were persistent and 45.1% were non-persistent; 7.6% of non-persistent individuals restarted. Mean ± SD age was 14.7 ± 10.8 vs. 16.5 ± 11.6 years and median ± IQR time on TROF was 14.3 ± 4.6 vs. 3.0 ± 3.8 months, respectively. Over 75% remained on treatment beyond 3 months, and more than half continued through study follow-up. Mean twice daily (BID) TROF dose was lower among persistent (7422.0 mg) vs. non-persistent (7850.8 mg) at RX1 and increased to 7953.7 mg vs 8423.4 mg, respectively at RX2. Thereafter, the persistent individuals maintained stable dosing, while the non-persistent showed greater fluctuation over time. Similar patterns were observed for %TDD. Older age and history of infectious disorders were significantly associated with non-persistence. CONCLUSIONS: In this real-world analysis, more than half of RTT individuals remained persistent on TROF for ≥14 months. Stable dosing patterns were observed among persistent individuals, while greater dose variability was observed among non-persistent individuals. Thus, these findings may provide guidance to clinicians about long-term TROF use in real-world practice.
Common Questions
What is Rett Syndrome?
Rett syndrome is a rare genetic condition that affects brain development, mainly in girls. After a period of typical early development, children lose purposeful hand skills and speech. Research into gene therapies and other treatments is progressing.
How many clinical trials are available for Rett Syndrome?
RareWays currently indexes 81 clinical trials for Rett Syndrome, of which 20 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Rett Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Rett Syndrome.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.